Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
20,714 total articles
Beta Bionics announced a 57% year-over-year increase in net sales for Q1 2026, driven by growth in both Durable Medical Equipment and Pharmacy Benefit Plan channels. The company improved its gross margin significantly and reduced its net loss compared to Q1 2025. Beta Bionics also raised its full-year 2026 revenue and gross margin guidance, reflect…
Olema Oncology announced it will present initial Phase 1 clinical data for its investigational drug OP-3136, a novel selective KAT6A/B inhibitor, at the 2026 ASCO Annual Meeting. The company will also provide updates on its ongoing Phase 3 OPERA-02 trial involving palazestrant plus ribociclib for advanced breast cancer. OP-3136 shows potent anti-pr…
Wave Life Sciences, a biotechnology company developing RNA-based medicines, has filed for shareholder and Singapore High Court approvals to redomicile its parent company from Singapore to the United States. The move aims to position the company advantageously for future growth and regulatory alignment, subject to customary approvals and closing con…
TrustCo Bank Corp NY reported a net income of $16.3 million for the first quarter of 2026, a 14.1% increase from the prior year. The bank's net interest income grew 10.7% to $44.7 million due to successful loan portfolio repricing and disciplined deposit pricing strategies, which led to a 20 basis point expansion in net interest margin to 2.84%. Lo…
Cytokinetics, a biopharmaceutical company specializing in cardiac muscle biology, announced its plan to release first quarter 2026 financial results on May 5, 2026, followed by a management conference call to discuss its financial performance and business updates. The company is advancing its pipeline of cardiac therapies, including the approved dr…
Belite Bio has initiated the rolling submission of a New Drug Application (NDA) to the FDA for tinlarebant, an oral therapy aimed at treating Stargardt disease type 1 (STGD1). The drug has received Breakthrough Therapy Designation and is backed by positive Phase 3 clinical data. The company plans to complete submission by Q2 2026 and is preparing f…
Farmers & Merchants Bancorp, Inc. (Nasdaq: FMAO), parent company of F&M Bank, announced the appointment of Shalini Singhal as Chief Information and Technology Officer. Singhal, previously the Chief Information Officer, will lead technology strategy focusing on innovation, digital transformation, and cybersecurity to support business growth and oper…
Fortinet Inc. has been honored as the 2026 Google Cloud Partner of the Year for Workload Security, recognizing its FortiCNAPP platform's innovative integration and protection of cloud workloads across hybrid and multi-cloud environments. The award emphasizes Fortinet's leadership in cloud security and its collaborative partnership with Google Cloud…
Sports Entertainment Gaming Global Corporation's subsidiary Quadrant has released a high-engagement YouTube video featuring Formula 1 drivers Carlos Sainz Jr. and Lando Norris, celebrating the 100th anniversary of karting. The campaign generated over four million views and significant social media impressions, reinforcing Quadrant's content strateg…
Independent Bank Corporation announced a quarterly cash dividend of $0.28 per share payable on May 14, 2026, to shareholders of record as of May 4, 2026. The Michigan-based community bank holds approximately $5.5 billion in assets and provides a full range of financial services throughout Michigan's Lower Peninsula.
SiriusPoint Ltd has received an upgrade from S&P Global Ratings on its core insurance operating subsidiaries to 'A' from 'A-', marking the company's third upgrade this year. The holding company rating was also raised to 'BBB+' from 'BBB' with a stable outlook. The upgrades are attributed to SiriusPoint's consistent underwriting performance, de-risk…
Royalty Pharma plc has announced the establishment of the Royalty Pharma Translational Prize, an annual $1 million award recognizing scientists who have successfully translated fundamental scientific discoveries into impactful new medicines. The prize aims to encourage translational research and will be awarded by an independent committee chaired b…
OpenTable, part of Booking Holdings, Inc., announced its annual Top 100 Brunch and Lunch Restaurants in Canada for 2026 and shared consumer trends for Mother’s Day dining, revealing that 65% of Canadians consider dining out an important part of their celebration. The data highlights evolving celebration styles including solo dining, larger family g…
United Fire Group, Inc. announced it will release its first quarter 2026 earnings results after market close on May 5, 2026, followed by an earnings call on May 6. The company invites analysts, investors, and stakeholders to participate via teleconference or webcast. The event will be archived for replay and a transcript will be available. United F…
Revolution Medicines announced that detailed results from its pivotal Phase 3 RASolute 302 clinical trial of daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in previously treated metastatic pancreatic ductal adenocarcinoma patients, will be presented at the 2026 ASCO Annual Meeting. The topline data showed statistically significant and cli…
Northeast Bank announced it will release its fiscal 2026 third quarter earnings on April 27, 2026, followed by a conference call on April 28, 2026. The call will be hosted by senior executives and available via live webcast and phone. Northeast Bank operates as a national lender and community bank, focusing on commercial real estate loans and small…
Alexander's, Inc., a New York City-based real estate investment trust, will release its Q1 2026 earnings on May 4, 2026, before market open. Vornado Realty Trust, the manager of Alexander's operations, will host a conference call on May 5, 2026, discussing quarterly results including those related to Alexander's. The company highlighted typical for…
Black Diamond Therapeutics announced multiple presentations at the 2026 ASCO Annual Meeting showcasing Phase 2 data of their brain-penetrant EGFR inhibitor, Silevertinib, in non-small cell lung cancer (NSCLC) and glioblastoma (GBM) patients. Early data indicate promising efficacy and safety profiles, including a 60% objective response rate in front…
Vornado Realty Trust announced it will release its first quarter 2026 earnings report on May 4, 2026, after the NYSE closes. The company will host a conference call and webcast on May 5, 2026 to discuss the quarterly results. Forward-looking statements highlight risks related to interest rate fluctuations, inflation, and their potential impact on t…
Regeneron Pharmaceuticals reported positive Phase 3 NIMBLE trial results for cemdisiran, an investigational siRNA therapy targeting complement factor 5 (C5), demonstrating rapid, deep, and sustained disease control in adults with generalized myasthenia gravis (gMG). The trial met primary and key secondary endpoints at 24 weeks, showing significant …
Zentalis Pharmaceuticals announced that an abstract highlighting results from Part 1 of their MUIR trial, testing azenosertib in combination with paclitaxel for platinum-resistant ovarian cancer, has been accepted for presentation at the ASCO 2026 Annual Meeting. Azenosertib, a first-in-class WEE1 inhibitor, is being developed as a biomarker-driven…
Skyworks Solutions, Inc. will release its second quarter fiscal 2026 earnings on May 5, 2026, followed by a conference call to discuss results and business outlook. The company provides analog and mixed-signal semiconductors across various sectors including wireless networking, aerospace, automotive, and consumer electronics.
Immatics N.V. announced that four abstracts from its clinical cell therapy and bispecific T-cell engager pipeline have been selected for oral presentations at the 2026 ASCO Annual Meeting. Data highlights include Phase 1b results of anzu-cel in melanoma, updated Phase 1a/b data for second-generation IMA203CD8 in gynecologic cancers, findings on PRA…
Aprea Therapeutics announced that early results from their first-in-human Phase 1 trial of the WEE1 inhibitor APR-1051 in advanced solid tumor patients have been accepted for presentation at the 2026 ASCO Annual Meeting. This milestone highlights progress in developing targeted therapies for biomarker-defined cancers and underscores the company's f…
NextCure, Inc. announced that Phase 1 clinical data for SIM0505, an investigational antibody drug conjugate targeting Cadherin-6 for the treatment of advanced solid tumors, will be presented at ASCO 2026. The results underscore forward progress in NextCure's oncology pipeline, focusing on innovative therapies for cancer including difficult-to-treat…
